About The Journal
  Aims and Scope
  Editorial Board
  Submit a Manuscript 
  Subscription Information
  Guidelines for Publication
  Ethics
Articles & Issues
  Search
  Issue
  Online First
  KJChE on
For Authors
  Instructions to Authors
  Ethical Responsibilities of
  Authors in KJChE
  Ethics in Publishing
  Peer Review Process
  Author's Checklist
  Copyright Transfer Form
Contact us
 
 
 
Issue
Korean Journal of Chemical Engineering,
Vol.30, No.1, 238-244, 2013
Physicochemical characterization and dissolution enhancement of loratadine by solid dispersion technique
Bandari S, Jadav S, Eedara BB, Jukanti R, Veerareddy PR
The purpose of this investigation was to enhance the dissolution rate of loratadine using polyethylene glycol 6000 (PEG) solid dispersions (SDs). The solubility behavior of loratadine in the presence of polyethylene glycol 4000 and polyethylene glycol 6000 in water showed linear increase with increasing concentrations of PEG, indicating AL type solubility diagrams. SDs of loratadine with PEG 6000 were prepared at 1 : 1, 1 : 3, 1 : 5, 1 : 7 and 1 : 9 ratios by the solvent evaporation method. Solid dispersions were characterized for drug content, dissolution behavior and for physicochemical characteristics. The dissolution rate of loratadine was enhanced rapidly with increasing concentrations of PEG 6000 in SDs. Fourier transform infrared (FTIR) studies showed the stability of loratadine and the absence of a well-defined loratadine - PEG 6000 interaction. Differential scanning calorimetry (DSC) and X-ray powder diffractometry (XRD) studies revealed the amorphous state of loratadine in SDs of loratadine with PEG 6000 which was further confirmed from scanning electron microscopy (SEM) studies. The flow properties of the blend, physical characteristics and disintegration time of the tablets formulated indicated that PEG 6000 SD can be used to formulate fast release loratadine tablets.
Keywords: Loratadine; Phase Solubility; Polyethylene Glycol; Solid Dispersion
[References]
  1. Horter D, Dressman JB, Adv. Drug Deliv. Rev., 25, 3, 1997
  2. Franco M, Trapani G, Latrofa A, Tullio C, Provenzano MR, Serra M, Muggironi M, Biggio G, Liso G, Int. J. Pharm., 225, 63, 2001
  3. Ghorab MK, Adeyeye MC, Pharm. Dev. Technol., 6, 305, 2001
  4. Nokhodchi A, Javadzadeh Y, Reza M, Barzegar jalali M, J.Pharm. Pharm. Sci., 8, 18, 2005
  5. Kim CK, Cho YJ, Gao ZG, J. Control. Rel., 70, 149, 2001
  6. Elaine ML, Gary GL, Eugene RC, Eur. J. Pharm. Sci., 18, 113, 2003
  7. Serajuddin ATM, J. Pharm. Sci., 88, 88, 1999
  8. Leuner C, Dressman J, Eur. J. Pharm. Biopharm., 50, 47, 2000
  9. Teofilo V, Bruno S, Paulo C, Drug Discov. Today., 12, 1068, 2007
  10. Khan GM, Zhu JB, Drug Dev. Ind. Pharm., 24, 455, 1998
  11. Kearney AS, Gabriel DW, Mehta SC, Radebaugh GW, Int. J. Pharm., 104, 169, 1994
  12. Potluri RHK, Bandari S, Jukanti R, Veerareddy PR, Arch.Pharm. Res., 34, 51, 2011
  13. Okonogi S, Oguchi T, Yonemochi E, Puttipipatkhachorn S, Yamamoto K, Int. J. Pharm., 156, 175, 1997
  14. Frances C, Veiga MD, Espanol OM, Cadorniga R, Int. J.Pharm., 77, 193, 1991
  15. Ter Laak AM, Tsai RS, Donne-Op den Kelder GM, Carrupt PA, Testa B , Timmerman H, Eur. J. Pharm. Sci., 2, 373, 1994
  16. Ter Laak AM, Bijloo GJ, Fischer MJE, Donne-Op den Kelder GM, Wilting J, Timmerman H, Eur. J. Pharm. Sci., 4, 307, 1996
  17. Seghal A, J. Srivastava and V. K. Arora, Patent No. WO 2004082589A2, 2004
  18. Abdel-Rahman SI, Ahmad SM, Samy IM, Badawy AMM, Ethiop. Pharm. J., 17, 1, 1999
  19. Omar L, El-Barghouthi MI, Masoud NA, Abdoh AA, Al Omari MM, Zughul MB, Badwan AA, J. Solution. Chem., 36, 605, 2007
  20. Damian F, Blaton N, Naesens L, Balzarini J, Kinget R, Augustinjns P, Mooter GV, Eur. J. Pharm. Sci., 10, 311, 2000
  21. Staniforth JN, Pharmaceutics, in: M. E. Aulton (Ed.), The Science Dosage Form Design, Churchill, Livingstone, 610, 1988
  22. Carr RL, Chem. Eng., 72, 163, 1965
  23. Khan KA, J. Pharm. Pharmacol., 27, 48, 1975
  24. Barzegar-Jalali M, Maleki N, Garjani A, Khandar AA, Haji-Hosseinloo M, Jabbari R, Dastmalchi S, Drug Dev. Ind. Pharm., 28, 681, 2002
  25. Zerrouk N, Chemtob C, Arnaud P, Toscani S, Dugue J, Int. J.Pharm., 225, 49, 2001
  26. Mukne AP, Nagarsenker MS, AAPS PharmSciTech., 5, 19, 2004
  27. Shah JC, Chen JR, Chow D, Int. J. Pharm., 113, 103, 1995
  28. Serajuddin ATM, Sheen PC, Augustine MA, J. Pharm.Sci., 79, 463, 1990
  29. Tang L, Khan SU, Muhammad NA, Pharm. Dev. Technol., 6, 531, 2001
  30. Khan N, Craig DQM, J. Control. Rel., 93, 355, 2003
  31. Hancock BC, Zographi G, J. Pharm. Sci., 86, 1, 1997
  32. Shin SC, Kim J, Int. J. Pharm., 251, 79, 2003
  33. Walker GM, Holland CR, Ahmad MMN, Craig DQM, Chem. Eng. Sci., 60(14), 3867, 2005
[Cited By]
  1. Sunkavalli S, Eedara BB, Janga KY, Velpula A, Jukanti R, Bandari S, Korean Journal of Chemical Engineering, 33(3), 1115, 2016
  2. Rostamian H, Lotfollahi MN, Mohammadi A, Korean Journal of Chemical Engineering, 37(12), 2295, 2020
참고문헌정보(참고문헌, 인용문헌)는 화학공학소재연구정보센터에 의해 제공되고 있습니다.